References
- Goebel MU, Baase J, Pithan V, Exton M, Saller B, Schedlowski M, Limmroth V. Acute interferon beta-1b administration alters hypothalamic-pituitary-adrenal axis activity, plasma cytokines and leukocyte distribution in healthy subjects. Psychoneuroendocrinology 2002;27: 881–92.
- Then BF, Kumpfel T, Yassouridis A, Lechner C, Holsboer F, Trenkwalder C. Acute and chronic neuroendocrine effects of interferon-beta 1a in multiple sclerosis. Clin Endocrinol (Oxf) 2007;66:295–303.
- Hosback S, Hardiman O, Nolan CM, Doyle MA, Gorman G, Lynch C, O’Toole O, Jakeman P. Circulating insulin-like growth factors and related binding proteins are selectively altered in amyotrophic lateral sclerosis and multiple sclerosis. Growth Horm IGF Res 2007;17:472–9.
- Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Bruce JN. Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly. Pituitary 2003;6:175–80.
- Caraccio N, Dardano A, Manfredonia F, Manca L, Pasquali L, Iudice A, Murri L, Ferrannini E, Monzani F. Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-beta 1a or 1b therapy: predictive factors of thyroid disease development and duration. J Clin Endocrinol Metab 2005;90:4133–7.
- Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jorgensen K, Muller J, Hall K, Skakkebaek NE. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994;78:744–52.
- Frystyk J, Dinesen B, Orskov H: Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Regul 1995;5: 169–76.
- Frystyk J, Freda P, Clemmons DR. The current status of IGF-I assays – a 2009 update. Growth Horm IGF Res 2010;20:8–18.
- Chen JW, Ledet T, Orskov H, Jessen N, Lund S, Whittaker J, De MP, Larsen MB, Christiansen JS, Frystyk J. A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am J Physiol Endocrinol Metab 2003;284:E1149–E55.
- Frystyk J, Brick DJ, Gerweck AV, Utz AL, Miller KK. Bioactive insulin-like growth factor-I in obesity. J Clin Endocrinol Metab 2009;94:3093–7.
- Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010;95:3141–8.
- Fuglsang J, Sandager P, Moller N, Fisker S, Frystyk J, Ovesen P. Peripartum maternal and foetal ghrelin, growth hormones, IGFs and insulin interrelations. Clin Endocrinol (Oxf) 2006;64:502–9.
- Scarisbrick IA. The multiple sclerosis degradome: enzymatic cascades in development and progression of central nervous system inflammatory disease. Curr Top Microbiol Immunol 2008;318:133–75.
- Del MP, Bernasconi D, De CV, Randazzo M, Meozzi M, Badaracco B, Mesiti S, Marugo M. Endocrine evaluation in patients treated with interferon-alpha for chronic hepatitis C. Horm Res 1995;44:105–9.
- Vitale G, van Koetsveld PM, de Herder WW, van der Wansem K, Janssen JA, Colao A, Lombardi G, Lamberts SW, Hofland LJ. Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells. Am J Physiol Endocrinol Metab 2009;296:E559–66.